Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
Authors:
Open Access
- 1 November 2017
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 25, 50-57
Abstract
No abstract availableKeywords
Funding Information
- Millennium Pharmaceuticals Inc.
This publication has 28 references indexed in Scilit:
- An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesLeukemia Research Reports, 2014
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin LymphomasJournal of Clinical Oncology, 2014
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- Aurora A kinase (AURKA) in normal and pathological cell divisionCellular and Molecular Life Sciences, 2012
- Association of Aurora‐A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiationCancer, 2011
- Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic AssaysClinical Cancer Research, 2011
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaBlood, 2010
- Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinomaHead & Neck, 2008
- Aurora-A and p16 Polymorphisms Contribute to an Earlier Age at Diagnosis of Pancreatic Cancer in CaucasiansClinical Cancer Research, 2007
- Aurora- A/STK15 T + 91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer typesCarcinogenesis, 2005